-

DermTech Announces Release Date for First-Quarter 2022 Financial Results

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, will host a conference call and webcast on Tuesday, May 3, 2022 at 5:00 p.m. Eastern Time (ET) to discuss the Company's first-quarter 2022 operating and financial highlights. In advance of the call on May 3, 2022, DermTech will issue its first-quarter 2022 earnings press release. To participate in the teleconference, callers can dial the following numbers:

844-467-7114 (toll-free, U.S.)

409-231-2086 (international)

Conference ID: 6584229

For those unable to participate in the live call and webcast, a webcast replay will be available on the Company’s website shortly after the conclusion of the call.

About DermTech:
DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. For additional information, please visit DermTech.

Contacts

DermTech
Steve Kunszabo (Senior Director, Investor Relations)
steve.kunszabo@dermtech.com

DermTech, Inc.

NASDAQ:DMTK

Release Versions

Contacts

DermTech
Steve Kunszabo (Senior Director, Investor Relations)
steve.kunszabo@dermtech.com

More News From DermTech, Inc.

DermTech Adds Approximately 7 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced a favorable coverage policy from Highmark Inc. (Highmark). Highmark and its Blue-branded affiliates provide health insurance to approximately 7 million members in Pennsylvania, West Virginia, Delaware and New York. The Pigmented Lesion Assay (PLA), the foundational assay of the DMT, is an innovative, non-invasi...

DermTech Announces Restructuring to Prioritize Growth Opportunities and Streamline Operations

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced restructuring actions that are intended to prioritize the significant growth opportunities for the DermTech Melanoma Test (DMT), streamline operations, suspend pipeline programs and significantly reduce overall operating expenses. Following a detailed review of its growth opportunities and operations, DermTech...

ECRI Completes Evaluation of the Pigmented Lesion Assay (PLA), the Foundational Assay for the DermTech Melanoma Test (DMT)

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that ECRI completed its evaluation of the Pigmented Lesion Assay (PLA), the foundational assay for the DermTech Melanoma Test (DMT), and changed its rating from ‘Inconclusive’ to ‘Somewhat Favorable’. ECRI is an independent, nonprofit organization focused on healthcare technology evaluation and safety to impr...
Back to Newsroom